Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entelon vs Celebrex in knee osteoarthritis (12-week, phase III)
KCT0000629Phase 3Recruiting
- Sponsor
- Hanlim Pharm
- Start
- Jul 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of grape seed extract in knee osteoarthritis (OA) (2 arms), sponsored by Hanlim Pharm. Primary endpoint: Primary efficacy and safety endpoints. Started Jul 2012; status: recruiting.
02
Drugs
grape seed extract
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on KCT0000629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0000629.